Anti-diabetic potential of Artemisia monosperma Delile extract related to anti-inflammatory, antioxidant, and wound-healing properties Authors: Hanaa B Atya, Mohamed S Mady, Ola Nosseir, Fatma A Moharram, Nashwa F Tawfik, Nashwa E Hashad Published: 2026 ABSTRACT AbstractArtemisia monosperma Delile (Asteraceae) is traditionally used for gastrointestinal issues and diabetes. This study aimed to characterize its phenolic profile and evaluate the molecular basis for its antioxidant, anti-inflammatory, and antidiabetic properties. The defatted 80% aqueous methanol extract (DAME) of A. monosperma aerial parts was profiled by HPLC-HRMS to identify phenolic compounds. Antihyperglycemic activity was tested via the Sucrose Loading Model (SLM) and a Type 2 diabetes model. Anti-inflammatory effects were measured in LPS-stimulated RAW264.7 cells by TNF-α and CRP gene expression. Wound-healing potential was evaluated in BJ cells, and antioxidant activity was assessed against superoxide, DPPH, and NO radicals. Molecular docking was used to examine the binding of the identified metabolites to targets, including inducible nitric oxide synthase (iNOS) and sulfonylurea receptor 1 (SUR1). The HRHPLC/MS analysis of the DAME of A. monosperma tentatively identified 25 secondary metabolites in the negative mode, including twelve phenolic acid derivatives, eight flavonoid compounds, and five miscellaneous terpenes. The DAME exhibits potent antihyperglycemic activity, with a 300 mg% dose reducing blood glucose levels by approximately 26% in a Type 2 diabetes model, comparable to diamicron. It also shows strong anti-inflammatory effects, reducing TNF-α and CRP gene expression by 66% and 82%, respectively, in LPS-stimulated RAW264.7 cells. Furthermore, it enhances wound healing, achieving approximately 79% closure in treated BJ cells compared to 58% in controls, and exhibits antioxidant activity. The identified library of compounds 1–25 was virtually screened against (iNOS) and (SUR1) to assess their binding affinities for each target. The binding modes of the compounds with the lowest energy scores for each were investigated. Different compounds demonstrated stronger affinities to each target than the co-crystallized ligand, among which compounds 4, 9, 11, and 14 possessed the lowest binding energies to both. A. monosperma DAME contains a variety of phenolic compounds and shows a potent multi-functional agent possessing anti-diabetic, anti-inflammatory, wound healing, and antioxidant activities, suggesting its therapeutic potential. However, more research is necessary to confirm its safety for clinical application. Keywords: Antidiabetic, Anti-inflammatory, Antioxidant, Artemisia monosperma, Polyphenols, Docking studySubject terms: Biochemistry, Computational biology and bioinformatics, Drug discovery, Plant sciences Introduction Recently, exposure to different risk issues and harmful lifestyles has contributed to the progression of chronic degenerative diseases, such as diabetes mellitus1. Diabetes is a serious illness and is one of the top ten causes of death among adults worldwide2. It results from several disorders affecting fat, carbohydrate, and protein metabolism, caused by insulin insufficiency, hyperglycemia, or both, leading to metabolic alterations that can ultimately be fatal3. Diabetes is classified into three types: Type 1 diabetes mellitus (T1DM) is an autoimmune disease marked by insulin deficiency resulting from the loss of pancreatic β-cell function4. In contrast, type 2 diabetes mellitus (T2DM), a metabolic disorder, accounts for approximately 90% of cases and is characterized by hyperglycemia, primarily due to decreased insulin sensitivity in the liver, skeletal muscles, and adipose tissue, or impaired insulin signaling2. Gestational diabetes, which occurs during pregnancy and results from progressive insulin resistance, serves as a risk factor for developing T2DM later in life4. Chronic hyperglycemia caused by diabetes can lead to numerous functional and structural disorders because of the highest oxidative stress and inflammation5. Additionally, chronic diabetes can result in myocardial infarction and peripheral vascular disease, retinopathy, nephropathy, and neuropathy6. Inflammation is a self-defense mechanism to begin the healing process. Plentiful diseases, comprising diabetes, atherosclerosis, neurodegeneration, arthritis, Alzheimer’s disease, and cancer, are induced by chronic inflammation. Diabetes is a lifestyle ailment with persistent hyperglycemia and complications, including delayed wound healing, hypertension, neuropathy, and tissue hypoxia caused by impaired metabolism of carbohydrates, proteins, and lipids, leading to hyperglycemia7. Therefore, research into anti-inflammatory mechanisms may offer a novel approach to reducing the inflammatory consequences of diabetes and promoting wound healing. Despite recent advances in wound care products, traditional remedies based on natural ingredients, such as plant extracts and honey, remain promising alternatives. Moreover, achieving effective glycemic control is the primary goal of diabetes treatment, as it helps prevent microvascular, macrovascular, and neurological complications8. Excessive generation of reactive oxygen species (ROS) by hyperglycemia leads to oxidative damage to biomolecules, contributing to diabetic complications9. Excess free radicals deplete antioxidant defenses, thereby increasing oxidative stress in diabetes10. ROS-mediated tissue oxidation promotes insulin resistance, impairs insulin signaling, and causes β-cell destruction11. Moreover, it is linked to diabetes complications; consequently, reducing oxidative stress in diabetes can help minimize the damage to organs and enhance patients’ quality of life. Also, elevated oxidative stress often triggers chronic inflammation12, and the progression of diabetes is associated with heightened release of pro-inflammatory markers in response to oxidative stress. Excessive activation of the inflammatory response results in more organ damage, higher free radical levels, and the progression of diabetic complications. Consequently, anti-inflammatory agents play a crucial role in the treatment of diabetes. Currently, diabetes management relies on anti-hyperglycemic drugs and insulin therapy. On the other hand, these treatments are not fully effective and may cause a range of side effects13. Moreover, they are often costly and difficult to access in developing countries14. As a result, medicinal plants, particularly those rich in phenolic compounds, offer a promising source for developing new antidiabetic agents because of their effectiveness, accessibility, and low toxicity. In recent years, phenolic compounds have received significant attention in scientific research due to their antioxidant13, anti-inflammatory15, and antihyperglycemic activities16, making them promising agents for the management of diabetes and its complications15. Genus Artemisia (Family Asteraceae) belongs to the tribe Anthemideae. It includes about 500 species of small shrubs and herbs worldwide, most of which are aromatic16. Artemisia monosperma Delile is commonly known as Sweet Annie, wormwood, or Qing Hao, and as Al-Ader’ in Egypt17. It is an aromatic, perennial green shrub native to Egypt and widely cultivated in other Arab countries, Africa, and China18. It is traditionally used, particularly by Bedouins of the Sinai Peninsula, for gastrointestinal disorders19, diabetes20, rheumatic pain, and fever21. Its dried leaves are also widely used in Egypt, alongside other Artemisia species, to prepare herbal tea with anthelmintic properties22. A. monosperma has been reported to be a rich source of various phenolic compounds17,23–28. Furthermore, it has been reported that the leaves of A. monosperma exhibit antimicrobial29,30, insecticidal31,32, and antimalarial31,32 properties. However, a scientific gap exists in understanding the mechanistic basis for these effects. Modern biological research establishes that chronic metabolic and digestive disorders are intrinsically linked to oxidative stress and sustained inflammatory responses33. Therefore, evaluating the antioxidant and anti-inflammatory activities of the DAME extract is necessary to validate its systemic therapeutic efficacy. Furthermore, since traditional skin treatments with Artemisia involve the repair of damaged tissue, investigating its wound-healing potential, which requires a coordinated reduction in inflammation and oxidative damage, offers a functional model to assess its regenerative properties34. Additionally, continuation of our work on the aerial parts of A. monosperma28. This study aimed to tentatively identify the phenolic compounds in the defatted aqueous methanol extract (DAME) using HRHPLC/MS. Furthermore, it evaluates the antidiabetic, anti-inflammatory, antioxidant, and wound healing activities of DAME using in vivo and in vitro models to provide mechanistic validation of its traditional applications. Finally, to better understand the molecular basis of these activities, a comprehensive molecular docking analysis was performed to assess the binding affinities of the identified metabolites for key therapeutic targets, including inducible nitric oxide synthase (iNOS) and sulfonylurea receptor 1 (SUR1). Materials and methods Plant material A. monosperma Delile aerial parts were collected from Al-Ein Alsokhna, a coastal region on the Red Sea in Egypt, in August 2022 at the end of the flowering stage, following the local garden`s guidelines for collection and complies with the collection legislation of Egypt, which comply with the IUCN policy statement on research involving species at risk of extinction and convention on the trade in endangered species of wild fauna and flora. Prof. Abduo M. Hamed, a Plant Ecology Professor at the Faculty of Science, Al-Azhar University, Cairo, Egypt, confirmed the plant identification. The plant was stored in the Pharmacognosy Department herbarium at the Faculty of Pharmacy, Capital University (formerly Helwan University), Cairo, Egypt, under the identifier 37 Amo 2/2023. Chemicals and reagents Methanol, n-butanol, acetic acid, and n-hexane were supplied by El Nasr Pharmaceutical Chemicals Co. (Gesr El Suez, Cairo, Egypt). Streptozotocin, Naturstoff reagent, FeCl3, and ascorbic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA). Diamicron→ 80 mg (Servier Egypt, Cairo Governorate, Egypt). Preparation of the defatted aqueous extract (DAME) A. Monosperma aerial parts (250 g) were extracted with 80% aqueous methanol under reflux (3 × 4 L), then filtered. The solvents were removed under reduced pressure at 50 °C, yielding 15 g of dry extract. The residue was defatted with n-hexane under reflux (4 × 1.0 L), then the hexane was removed under reduced pressure at low temperature. The dried DAME (9 g) was subjected to 2-D paper chromatography (2D-PC) using the upper layer of n-butanol: acetic acid: water (4:1:5, BAW) for the first run, and 15% aqueous acetic acid (HAc), followed by examination under UV light before and after spraying with Naturstoff reagent and FeCl3 reagents. HPLC/HR MS analysis of DAME The analysis utilized a 6530 Q-TOF LC/MS system (Agilent Technologies), equipped with an autosampler (G7129A), a Quat pump (G7104C), and a Column Comp (G7116A) for chromatographic separation. The injection volume was one µL. Analytes were separated on a Zorbax RP-18 column (Agilent Technologies; 150 mm × 3 mm, 2.7 μm) at a flow rate of 3 mL/min. Mass spectra were acquired in negative-ion mode using ESI, with a capillary voltage of 4000 V. Spectra ranged from m/z 50 to 3000. The gas temperature was maintained at 250 °C, and the drying-gas flow rate was 8 L/min. The skimmer and fragmentation voltages were set to 65 V and 130 V, respectively, and the collision energy was 10 V. The nebulization pressure was 58 psi. Compound identification was preliminarily assigned based on accurate mass values from HPLC–HRMS analysis, along with comparisons with reported compounds in the literature and spectral databases. Because of the experimental setup used, MS/MS fragmentation data and Δppm mass accuracy values were unavailable; thus, the suggested compounds should be regarded as tentative annotations. Mass accuracy (Δppm) was determined by (measured m/z − theoretical m/z)/theoretical m/z × 10⁶. For some peaks, the Δppm values were relatively high, so the related compound identifications are considered tentative. Evaluation of antidiabetic activity Animals Male Wistar albino rats (200–250 g) obtained from VACSERA (Helwan, Cairo, Egypt) were housed at the Faculty of Pharmacy, Capital University (formerly Helwan University), animal facility, and provided with pelleted food and water. The rats were acclimatized to a controlled environment with a 12-hour light-dark cycle for one week. The study protocol was approved by the Faculty of Pharmacy, Capital University (formerly Helwan University), animal ethics committee (No. 14A2024), and was conducted in accordance with EC Directive 86/609/EEC for animal experiments. At the end of the experimental period, rats were deeply anesthetized with an intraperitoneal injection of sodium pentobarbital (60 mg/kg). Following the confirmation of loss of pedal reflex, cervical dislocation was manually conducted by applying firm pressure at the base of the skull while pulling the tail to ensure quick separation of the cervical vertebrae35. Preparation of the extract for antidiabetic activity The A. monosperma DAME extract was weighed at 100, 200, and 300 mg and placed in a mortar. Subsequently, one drop of Tween 80 was added until complete dissolution. Subsequently, distilled water was added gradually to achieve the desired concentrations (100, 200, and 300 mg%). Subsequently, the extract was filtered and administered to the rats at weight-based doses. Preliminary oral toxicity evaluation A preliminary oral toxicity screening was performed to assess the safety of DAME in fasted male albino rats (200–250 g). The study involved three groups (n = 6). DAME was given via oral gavage at doses of 100, 200, and 300 mg/kg body weight following an overnight fast. The three tested doses (100, 200, and 300 mg/kg b.w.) were selected because they fall within the range reported in the literature for pharmacologically active, non-lethal doses of Artemisia extracts in rodents according to Moharram et al., 202136. Rats were monitored for 24 h for behavioral changes, such as tremors, convulsions, and incoordination, as well as respiratory issues like rapid or labored breathing. The dose levels were selected to provide an early indication of tolerability at relevant pharmacological doses, rather than to establish an LD₅₀ value. Evaluating the antihyperglycemic effects of A. monosperma DAME After overnight fasting, male albino rats (200–250 g; n = 6) were classified into five groups. The first group received the vehicle only (control). The second, third, and fourth groups were administered DAME extract by oral gavage at doses of 100, 200, and 300 mg, respectively. The fifth group received Diamicron® (gliclazide) as the reference drug at a dose of 80 mg. Thirty min later, rats were orally loaded with sucrose (10 g/kg) dissolved in distilled water. This high-dose challenge was selected to induce a pronounced glycemic peak and better evaluate the extract’s anti-hyperglycemic potential, following previously validated protocols37,38. BGLs were measured at 0 (before the sucrose load) and at 30, 60, 90, and 120 min. after the sucrose load using a glucometer (Gluco Dr Super Sensor, All Medicus Co., Ltd., Anyang, Gyeonggi, Korea) to calculate the glucose area under the curve (AUC)39. Diamicron→ (Gliclazide, 80 mg) was used as the reference drug. Induction of type-2 diabetes (T2D) in rats The potential antidiabetic effect of DAME was tested in diabetic rats made hyperglycemic by a 4-week high-fat diet (HFD) containing 60% fat, 20% protein, and 20% carbohydrate, with a total energy of 25.07 KJ/g. After overnight fasting, the rats were injected I.p. with 35 mg/kg streptozotocin, which was prepared in 0.05 M cold citrate buffer at pH 4.5. Blood glucose levels were measured with a glucometer after 2 days, and rats with BGL ≥ 200 mg/dL were included in the experiment40. Diabetic rats were randomly assigned to four groups (n = 6), with all groups fasted overnight before the first group received an oral vehicle (T2D control). The other three groups received diamicron as a standard antidiabetic drug (80 mg/kg) or DAME orally at specified doses (200 and 300 mg). After 1 h, each rat received an oral glucose dose of 1.0 g/kg. Blood glucose levels were then recorded at baseline (before glucose administration) and at 30, 60, 90, and 120 min. post-glucose load, using a glucometer. Anti-inflammatory effect of A. monosperma DAME RAW 264.7 culture and viability assay RAW 264.7 murine macrophages (ATCC, Manassas, VA, USA) were maintained in Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen/Life Technologies) supplemented with 10% fetal bovine serum (Hyclone, GE Healthcare, USA), insulin at a final concentration of 10 µg/mL, and 1% penicillin–streptomycin (Sigma-Aldrich, St. Louis, MO, USA). Cells were incubated at 37 °C in a humidified environment containing 5% CO₂. RAW cell viability was assessed using the MTT-based in vitro toxicology assay kit (Sigma-Aldrich, USA). Cells were seeded at 1.2–1.8 × 104 cells per well and incubated at 37 °C in a CO2-enriched incubator with different concentrations of DAME (250, 63, 16, 4, and 1.0 µg/mL) for 24 h. After treatment, MTT solution was added to each well and incubated at 37 °C for 4 h. The optical density at 590 nm was measured using a microplate reader (Sunrise, TECAN Inc., USA) to assess cell viability, and the results were compared with those of untreated control cells. Evaluation of inflammatory markers (TNF-α and CRP) by qRT-PCR RAW264.7 cells were plated at a density of 1 × 106 cells/well in 6-well plates and allowed to reach confluence. They were then treated with DAME at a concentration equivalent to 0.25 of the IC50 for two h, followed by the addition of 1 µg/mL LPS to induce inflammation. 24 h later, the cells were harvested for RNA extraction using a Qiagen RNA extraction kit (Sigma-Aldrich in Saint Louis, Missouri, USA). Reverse transcription was performed using a RevertAid™ H Minus Reverse Transcriptase kit (Sigma-Aldrich in Saint Louis, Missouri, USA), and mRNA levels of CRP and TNF-α were quantified using BioRad Sybr green PCR MMX with specific RT primers as provided in Table 1. qRT-PCR was conducted via a Rotor-Gene Q instrument (QIAGEN Hilden, Germany), and fold change was calculated using the 2−ΔΔCt method. Beta-actin (ACTB) was used as a housekeeping gene. All experiments were done in triplicate to ensure accuracy. Table 1Primers for CRP, TNF-α, and the housekeeping gene ACTB.TNF-αF 5’- GGTGCCTATGTCTCAGCCTCTT-3’R 5’- GCCATAGAACTGATGAGAGGGAG-3’CRPF 5’- TCGTGGAGTTCTGGGTAGATGG-3’R 5’- TTCCCACCGAAGGAATCCTGCT-3’ACTBF 5’- CATTGCTGACAGGATGCAGAAGG-3’R 5’-TGCTGGAAGGTGGACAGTGAGG-3’ Primers for CRP, TNF-α, and the housekeeping gene ACTB. Evaluation of wound healing BJ cell culture and treatment Human foreskin fibroblast (BJ) cells (CRL-2522; ATCC) were cultured in Dulbecco’s Modified Eagle Medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Sigma-Aldrich-Merck KGaA; Darmstadt, Germany) and 1% penicillin-streptomycin (Beijing Solarbio Science & Technology Co., Ltd.). The cells were maintained in a cell incubator (Thermo Fisher Scientific, Inc.) at 37 °C with 5% CO2 and full humidity. When BJ cells reached the logarithmic growth phase, they were seeded into 6-well plates at a density of 2 × 105 cells per well and incubated for 24 h. The wells were divided into control (untreated) cells and A. monosperma aerial parts DAME-treated cells. Wound-healing assay The migration of BJ cells was evaluated using a wound-healing assay. Cells from each group were prepared at a concentration of 3 × 105/mL and seeded into 6-well plates to form a cell monolayer. A scratch was created in the cell layer using a 10-µL pipette tip, and debris was removed. Images were captured at 0 and 24 h post-scratching with an inverted microscope (Olympus Corp.), and the wound-healing rate was quantified using ImageJ (version 1.46r; National Institutes of Health). Assessments of antioxidant activity DPPH radical scavenging activity The procedure followed the protocol of Sharma et al. (2009)41. A. Monosperma aerial parts DAME was applied in concentration series (12.5, 25, 50, 100, and 200) µg/mL. Ascorbic acid served as the reference, and DMSO as the negative control. Each measurement was done in triplicate. Nonlinear regression analysis was performed to determine the IC50, the concentration required to inhibit free radical formation by 50%. Superoxide radical inhibition activity (O2-.) The assay followed the standard procedure outlined by Xiang & Ning (2008). A. Monosperma aerial parts DAME at concentrations (12.5, 25, 50, 100, and 200 µg/mL) were tested. Each test was performed in triplicate. Ascorbic acid served as the reference, while DMSO was the negative control. The IC50 value was determined by nonlinear regression analysis. Nitric oxide (NO) scavenging activity It was evaluated using the methods outlined by42. Ascorbic acid served as the reference, and DMSO as the negative control. Absorbance was measured at 546 nm in triplicate. The IC50 value was obtained from the dose-response curve using non-linear regression analysis. Statistical analysis All results are expressed as Mean ± Standard Deviation (SD). Data was analyzed using One-way Analysis of Variance (ANOVA). Significant differences between the mean values of the treatment groups and the control groups were determined using Tukey’s post-hoc multiple comparison test. A p-value of less than 0.05 was considered statistically significant. Statistical analysis was performed using GraphPad Prism software version 9.0 (La Jolla, CA, USA). In silico molecular docking The structures of inducible nitric oxide synthase (iNOS), particularly its catalytic oxygenase domain, and the sulfonylurea receptor 1 (SUR1) with PDB ID of 3E7G43 and 6PZA44, respectively, were downloaded from the Protein Data Bank45. Both proteins were purified and prepared for docking using AutoDock Tools 1.5.746. The structures of compounds 1–25 were minimized and prepared with Open Babel47 in PyRx48. A grid box measuring 30 × 30 × 30 Å, centered at 55, 17, and 83, was set up for screening against iNOS. For SUR1, a grid box of the same size, centered at 203, 282, and 219, was used. The parameters for each protein were first validated by docking its co-crystallized ligand using AutoDock Vina49 through PyRx, and by calculating the root mean square deviation (RMSD). Compounds 1–25 were screened against each target using consistent parameters. The results were analyzed using Maestro 12.850. Results The 2-DPC of DAME revealed a mixture of polyphenolic compounds, as evidenced by its behavior under UV light and upon spraying with Naturstoff and FeCl3 reagents. HPLC/HRMS analysis for DAME of A. monosperma aerial part The HRHPLC/MS analysis of the DAME of A. monosperma tentatively identified 25 secondary metabolites in the negative mode, including phenolic acid derivatives, flavonoids, and terpenes (Table 2; Fig. 1). Table 2Tentative identification of metabolites in A. monosperma DAME extract by HPLC–HRMS based on accurate mass and literature comparison.NoCompound*Rt[M-H]-Theoretical [M–H]⁻ΔppmExact massMFReferences 1 Caffeoylquinic acid isomer2.99353.0813353.087818.4354.0951C16H18O9 24 2 Protocatechuic acid3.46153.0172153.01847.8154.0266C7H6O4 54 3 Adipostatin E3.82333.0669333.2666−334.2872C22H38O2 84 4 Sesamin4.52353.0813353.087818.4354.1103C20H18O6 64 5 Caftaric acid5.70311.0721311.0403-312.0481C13H12O9 51 6 Caffeic acid6.05179.0365179.034610.6180.0423C9H8O4 28,53 7 Dihydroartemisinic acid6.64235.0951235.1695−236.1776C15H24O2 85 8 Vanillic acid sulfate7.58247.0551247.0004−247.9991C8H8O7S 86 9 Dicaffeoylquinic acid7.81515.1099515.119017.7516.1268C25H24O12 24,51 10 Dihydroartemisinic aldehyde9.81219.0984219.1852−220.1827C15H24O 85 11 Caffeoyl feruloylquinic acid10.75529.1336529.13574.0530.1424C26H26O12 55 12 Isorhamnetin11.34315.0450315.050617.8316.0583C16H12O7 27 13 Malaferin B11.57435.1387435.129620.9436.1158C24H20O8 87 14 Chicoric acid hexoside isomer12.04635.1391635.151719.8636.1326C28H28O17 88 15 Taxifolin12.40303.1619303.0503−304.0583C15H12O7 60 16 Tricin13.34329.0651329.0452−330.0740C17H14O7 66 17 Rosmarinic acid14.04359.0784359.07791.4360.0845C18H16O8 53 18 Methylcatechin14.28303.1619289.0718-304.0947C16H16O6 53 19 Methoxy apigenin14.98299.0558299.05531.7300.0634C16H12O6 18,59 20 Protocatechuic acid-O-hexoside15.57315.0450315.050617.8316.0794C13H16O9 54 21 Eriodictyol16.86287.1590287.0553−288.0634C15H12O6 61 22 Feruoylquinic acid22.39367.1862367.1034−368.1107C17H20O9 55 23 Artecanin28.15277.2169277.1130−278.1154C15H18O5 63 24 p-coumaroyl ester29.91279.2336279.0452−280.0583C13H12O7 56 25 Pinocembrin31.56255.2300255.0661−256.0736C15H12O4 62 Tentative identification of metabolites in A. monosperma DAME extract by HPLC–HRMS based on accurate mass and literature comparison. Total negative ionization mode HRHPLC/MS chromatogram of the aerial parts of A. monosperma DAME. Phenolic acids Phenolic acids are commonly found throughout the genus Artemisia51. Based on their chemical scaffold, phenolic acids are sub-classified into hydroxybenzoic and hydroxycinnamic acid derivatives52. In the current study, we identified three hydroxybenzoic acid derivatives (2, 8, 20) and nine cinnamic acid derivatives (1, 5, 6, 9, 11, 14, 17, 22, and 24). Compounds 2, 8, and 20 were identified as protocatechuic acid, vanillic acid 4-sulfate, and protocatechuic acid -O-hexoside with m/z [M-H]− 153.0172, 247.0551, and 315.0450, respectively. Compound 6 was identified as caffeic with m/z [M-H]− 179.0365, while 1, 5, 9, 11, 14, 17 and 22 are caffeic acid derivatives; they were identified as caffeoylquinic acid isomer 1, caffeoltartaric acid 5 (caftaric acid), dicaffeoylquinic acid 9, caffeoylferuloylquinic acid 11, dicaffeoyl- tartaric acid hexoside 14 (chicoric acid hexoside isomer), rosmarinic acid 17 and 5-feruoylquinic acid 22 with m/z [M-H]− 353.0813, 311.0721, 515.1099, 529.1336, 636.512, 359.0784 and 367.1862, respectively. Moreover, one coumaric acid derivative, p-coumaroyl ester 24, with m/z [M-H]− 279.2336 was also identified. Compounds 1, 6, 9, 17, and 24 were previously identified from A. monosperma leaves24,28,51,53, while compounds 2, 5, 11, 20, and 22 were identified from the genus Artemisia before51,53–56. However, this is the first time these compounds have been identified from A. monosperma, along with compounds 4 and 18, which are reported here for the first time from the genus. Flavonoids Flavonoids are commonly found in the genus Artemisia57,58. They include flavonol derivatives such as isorhamnetin, 12, and dihydroquercetin (taxifolin) 15, with m/z [M-H]− 315.0450 and 303.1619, respectively; flavone derivatives like tricin, 16 (m/z [M-H]− 329.0651), and methoxy apigenin 19 [M-H]− 299.0558; flavanones such as eriodictyol 21 [M-H]− 287.1590 and pinocembrin, 25 [M-H]− 255.230; as well as flavan-3-ols like malaferin B, 13 and methylcatechin 18, with m/z [M-H]− 435.1387 and 303.1619, respectively. It was reported that compounds 12, 18, and 19 had previously been identified from A. monosperma18,26,27,53,59, while compounds 1560, 2161, and 2562 were previously identified in the genus, but for the first time from A. monosperma. Additionally, compounds 13 and 16 were identified for the first time from both the plant and genus. Miscellaneous Three sesquiterpenes are identified: dihydroartemisinic acid,7 ([M-H]− 235.0951); dihydroartemisinic aldehyde, 10 ([M-H]− 219.0984); and artecanin, 23 ([M-H]− 277.2169), a resorcinol derivative; adipostatin, 3 ([M-H]− 333.06690); and one lignan derivative, sesamin, 4 ([M-H]− 353.0813). Compounds 7 and 10 were previously identified from A. monosperma (El Naggar, 2012), while compounds 4 and 23 were previously reported from the genus63,64 and are reported here for the first time from the plant, along with compound 3. Anti-diabetic potential of A. monosperma DAME Preliminary oral toxicity evaluation No adverse effects were observed at the tested doses (100, 200, and 300 mg/kg) under the conditions of this study. Previous studies have shown low toxicity in certain Artemisia extracts. we cite specific research on an Artemisia extract made with a similar 80% aqueous methanol extract36, which more closely resembles the current DAME. Estimation of the antihyperglycemic activity The antihyperglycemic potential of A. monosperma DAME was evaluated using the SLM. As shown in Table 3, the DAME extract exhibited a dose-dependent reduction in the glucose area under the curve (AUC). While the lower doses showed a modest decrease, the 300 mg/kg dose significantly reduced the AUC by 19% compared with the SLM control group, demonstrating efficacy comparable to the reference drug, Diamicron®. Table 3Screening of A. monosperma DAME oral administration in normal rats on blood glucose levels using SLM.SampleconcAUC (mg/min/dL)% Reduction in BGL compared to controlDAME of A. monosperma100 mg%193.63 ± 16.12*13.90200 mg%192.08 ± 21.94*14.58300 mg%182.75 ± 17.81**18.73Diamicron®80 mg189.21 ± 10.45**15.86Data is presented as mean AUC ± SD. * Significant (P < 0.05), ** (P < 0.01) or *** (P < 0.001) compared to control group using One-way ANOVA followed by Tukey’s post-hoc test. SLM: sucrose load model. N = 6. Screening of A. monosperma DAME oral administration in normal rats on blood glucose levels using SLM. Data is presented as mean AUC ± SD. * Significant (P < 0.05), ** (P < 0.01) or *** (P < 0.001) compared to control group using One-way ANOVA followed by Tukey’s post-hoc test. SLM: sucrose load model. N = 6. Influence of DAME of A. monosperma on blood glucose levels in T2D rats A T2D animal model was used to investigate the antihyperglycemic effects of A. Monosperma aerial parts DAME after oral administration of the two selected doses, 200 and 300 mg%, compared with diamicon→. The findings indicated that 300 mg% significantly improved glucose tolerance, resulting in approximately a 26% decrease in blood glucose levels, an effect comparable to diamiconⓇ (26.9%) (Table 4). Table 4The antidiabetic effect of A. monosperma DAME by an OSTT in T2D rats.SampleconcAUC (mg/min/dL)% Reduction in BGLDAME of A. monosperma200 mg%756.63 ± 63.3503.34300 mg%578.54 ± 20.13***26.09Diamicron®80 mg572.15 ± 14.61***26.91Data is shown as mean AUC ± SD. ***: P < 0.001 compared to the control group using One-way ANOVA followed by Tukey’s post-hoc test. OSTT: oral sucrose tolerance test. (n = 6). The antidiabetic effect of A. monosperma DAME by an OSTT in T2D rats. Data is shown as mean AUC ± SD. ***: P < 0.001 compared to the control group using One-way ANOVA followed by Tukey’s post-hoc test. OSTT: oral sucrose tolerance test. (n = 6). The anti-inflammatory effect of A. Monosperma DAME To evaluate the anti-inflammatory effects, we measured changes in TNF-α and CRP gene expression in RAW264.7 cells following LPS stimulation. DAME exhibited significant anti-inflammatory activity (p < 0.001), with reductions of approximately 66% in TNF-α and 82% in CRP expression compared to LPS-treated control (Fig. 2). Additionally, DAME exerted a greater inhibitory effect on CRP expression (p < 0.001) than celecoxib, which reduced CRP expression by 70%. Anti-inflammatory effect of A. monosperma DAME in LPS-treated Raw cells, ***: P < 0.001 vs. LPS control, and # # #: P < 0.001 vs. celecoxib via one-way ANOVA, followed by post hoc test. Data are expressed as the mean ± SD of three experiments. Effect of A. monosperma DAME on wound healing The results of the wound-healing assay are shown in Fig. 3. Wound healing in A. Monosperma-treated BJ cells reached approximately 79% after 24 h, whereas control, untreated BJ cells reached about 58% after 24 h. Wound healing rate in case of DAME was significantly higher compared to control cells (p < 0.001). Effect of A. monosperma DAME on wound healing via BJ cells’ migration assay ***: P < 0.001 vs. control cell via unpaired t test. Data are expressed as the mean ± SD of three experiments. The antioxidant activity of A. monosperma aerial parts DAME The DAME of A. monosperma showed promising antioxidant activity compared to ascorbic acid. As shown in Table 5, the superoxide scavenging activity of DAME (IC50 = 11.05 µg/mL) demonstrated superior effects compared to ascorbic acid. Additionally, DAME exhibited good DPPH and NO scavenging activity (IC50 = 34.66 and 56.12 µg/mL, respectively) relative to ascorbic acid (Table 5). Table 5Evaluation of antioxidant activity of A. monosperma DAME.SamplesIC50 (µg/mL)DPPHSuperoxide radicalNitric oxideDAME34.6611.0556.12Ascorbic acid19.65 ± 0.3921.6 ± 0.4337.91Data is shown as mean ± SD. Evaluation of antioxidant activity of A. monosperma DAME. Data is shown as mean ± SD. In silico docking study The binding energies of the compounds screened in silico for their affinity to both iNOS and SUR1 are listed in Table 6. For iNOS, the energies ranged from − 10.2 to −6.3 kcal/mol, compared to −8.9 kcal/mol for the co-crystallized ligand (PDB ID: AT2, or ethyl 4-[(4-methylpyridin-2-yl) amino] piperidine-1-carboxylate). Similarly, for SUR1, energies ranged from − 11.0 to −6.1 kcal/mol, versus − 10.4 kcal/mol for the co-crystallized drug (glibenclamide). The RMSD values for each docked co-crystallized ligand, AT2 for iNOS and glibenclamide for SUR1, relative to their native structures were 0.511 and 1.512 Å, respectively. Table 6Virtual screening results against iNOS and SUR1.Ligand numberBinding energy (kcal/mol)Ligand numberLigand numberiNOSSUR1iNOSSUR1 1 −9.3−8.6 14 −10.0−9.8 2 −6.3−6.1 15 −9.0−9.5 3 −8.0−7.3 16 −7.7−8.8 4 −9.8−11.0 17 −10.1−8.4 5 −8.7−8.1 18 −8.0−8.8 6 −7.3−6.8 19 −8.6−9.4 7 −7.1−8.2 20 −8.4−8.0 8 −7.4−7.0 21 −9.3−9.4 9 −10.2−10.3 22 −9.7−8.8 10 −7.2−7.9 23 −7.6−8.0 11 −10.2−9.8 24 −8.4−7.7 12 −8.2−9.5 25 −8.9−9.1 13 −9.7−9.7 Co-crystallized a −8.9−10.4aCo-crystallized ligand: AT2 for iNOS or glibenclamide for SUR1. Virtual screening results against iNOS and SUR1. aCo-crystallized ligand: AT2 for iNOS or glibenclamide for SUR1. Ten compounds showed better binding affinities to iNOS than the co-crystallized ligand (i.e., with binding energies ≤ −9.0 kcal/mol), including compounds 9 and 11 (−10.2), 17 (−10.1), 14 (−10.0), 4 (−9.8), 13 and 22 (−9.7), 1 and 21 (−9.3), and 15 (−9.0). Fourteen other compounds possessed energy values ranging from − 8.9 to − 7.0 kcal/mol: compounds 25 (−8.9), 5 (−8.7), 19 (−8.6), 20 and 24 (−8.4), 12 (−8.2), 3 and 18 (−8.0), 16 (−7.7), 23 (−7.6), 8 (−7.4), 6 (−7.3), 10 (−7.2), and 7 (−7.1). The highest binding energy observed was − 6.3 kcal/mol for compound 2. The docking validation and binding modes of the top compounds with energies ≤ −9.0 kcal/mol for iNOS are shown in Table 7; Fig. 4A–H, and 5A–C. Table 7Binding interactions of top compounds to iNOS.Ligand numberHydrogen bondsInteracting moietiesCountLength (Å)LigandResidue 1 12.21Caffeoyl C = OGLN263 NH2 4 12.58Benzodioxole OVAL352 NH (backbone) 9 42.571.802.171.61Propenoate OQuinic acid COOHCaffeoyl OHCaffeoyl OHGLN263 NH2TYR347 OHTRP372 C = O (backbone)GLU377 COO− 11 22.102.43Caffeoyl C = OQuinic acid COOHTYR347 OHASP382 COO− 13 22.402.48Propenoate ODihydroxychromane OHGLN263 NH2TYR373 OH 14 22.202.33Caffeoyl C = OCaffeoyl OHTYR347 OHPRO350 C = O (backbone) 15 Nil––– 17 41.982.262.172.30Caffeoyl C = OCaffeoyl C = OPropanoic COOHCatechol OHTYR347 OHTYR373 OHASP382 COO−Heme COO− 21 22.062.40Dihydroxychromanone C = OCatechol OHTYR347 OHVAL352 NH (backbone) 22 22.092.00Propenoate OQuinic acid OHGLN263 NH2ASP382 COO− Binding interactions of top compounds to iNOS. 2.57 1.80 2.17 1.61 Propenoate O Quinic acid COOH Caffeoyl OH Caffeoyl OH GLN263 NH2 TYR347 OH TRP372 C = O (backbone) GLU377 COO− 2.10 2.43 Caffeoyl C = O Quinic acid COOH TYR347 OH ASP382 COO− 2.40 2.48 Propenoate O Dihydroxychromane OH GLN263 NH2 TYR373 OH 2.20 2.33 Caffeoyl C = O Caffeoyl OH TYR347 OH PRO350 C = O (backbone) 1.98 2.26 2.17 2.30 Caffeoyl C = O Caffeoyl C = O Propanoic COOH Catechol OH TYR347 OH TYR373 OH ASP382 COO− Heme COO− 2.06 2.40 Dihydroxychromanone C = O Catechol OH TYR347 OH VAL352 NH (backbone) 2.09 2.00 Propenoate O Quinic acid OH GLN263 NH2 ASP382 COO− Binding modes to iNOS: (A) Co-crystallized (teal) vs. docked (magenta) AT2. Compounds (B) 1 (Caffeoylquinic acid isomer), (C) 4 (sesamin), (D) 9 (dicaffeoylquinic acid), (E) 11 (caffeoylferuloylquinic acid), (F) 13 (malaferin B), (G) 14 (chicoric acid hexoside isomer), and (H) 15 (taxifolin). Ligands are displayed as ball-and-stick models, while residues and heme (HEM901) are shown as tubes. Hydrogen bonds are depicted as yellow dashed lines with their lengths in magenta. Binding modes to iNOS (continued): compounds (A) 17 (rosmarinic acid), (B) 21 (eriodyctiol), and (C) 22 (methylchlorogenate). Binding modes to SUR1: (D) Co-crystallized (teal) vs. docked (magenta) glibenclamide. Compounds (E) 4 (sesamin) and (F) 9 (dicaffeoylquinic acid). Ligands are displayed as balls and sticks, while residues and heme (HEM901) are shown as tubes. Hydrogen bonds are depicted as yellow dashed lines with their lengths in magenta. To SUR1, compound 4 showed a lower binding energy of −11.0 kcal/mol than that of the co-crystallized ligand. Additionally, compound 9 exhibited an energy of −10.3 kcal/mol, similar to that of glibenclamide. Eight other compounds had energy scores of ≤ −9.0 kcal/mol, including compounds 11 and 14 (−9.8), 13 (−9.7), 12 and 15 (−9.5), 19 and 21 (−9.4), and 25 (−9.1). Thirteen compounds displayed energy values ranging from − 8.9 to −7.0 kcal/mol: compounds 16, 18, and 22 (−8.8), 1 (−8.6), 17 (−8.4), 7 (−8.2), 5 (−8.1), 20 and 23 (−8.0), 10 (−7.9), 24 (−7.7), 3 (−7.3), and 8 (−7.0). Compounds 6 and 2 recorded the highest scores of −6.8 and − 6.1 kcal/mol, respectively. The docking validation and binding modes of the top compounds with energies of ≤ −9.0 kcal/mol to SUR1 are shown in Table 8; Fig. 6D–F, and 6A–H. Table 8Binding interactions of top compounds to SUR1.Ligand numberHydrogen bondsInteracting moietiesCountLength (Å)LigandResidue 4 41.992.422.31/2.52Benzodioxole OBenzodioxole OHexahydrofurofuran OASN437 NH2ASN1245 NH2ARG1246 NH2+/NH2 9 51.912.312.322.52/1.96Caffeoyl OHCaffeoyl OHCaffeoyl C = OCaffeoyl C = OSER376 C = O (backbone)ARG388 NH2+ASN1245 NH2ARG1246 NH2+/NH2 11 22.522.21Quinic acid COOHQuinic acid COOHTHR1242 OHASN1245 NH2 12 12.34Trihydroxychromone C = OARG1246 NH2+ 13 22.231.99Hydroxyphenyl OHDihydroxychromane OHASN437 C = OARG1300 NH2 14 42.312.372.232.17Caffeoyl OHCaffeoyl OHCaffeoyl C = OHexose CH2OHARG388 NH2+ARG388 NH2+ARG1246 NH2+ASN1293 NH2 15 12.26Trihydroxychromanone C = OARG1246 NH2+ 19 22.272.03Dihydroxychromone C = ODihydroxychromone OHARG1246 NH2+ARG1246 NH2+ 21 12.12Dihydroxychromanone C = OARG1246 NH2+ 25 22.302.14Dihydroxychromanone C = ODihydroxychromanone OHARG1246 NH2+ARG1246 NH2+ Binding interactions of top compounds to SUR1. 1.99 2.42 2.31/2.52 Benzodioxole O Benzodioxole O Hexahydrofurofuran O ASN437 NH2 ASN1245 NH2 ARG1246 NH2+/NH2 1.91 2.31 2.32 2.52/1.96 Caffeoyl OH Caffeoyl OH Caffeoyl C = O Caffeoyl C = O SER376 C = O (backbone) ARG388 NH2+ ASN1245 NH2 ARG1246 NH2+/NH2 2.52 2.21 Quinic acid COOH Quinic acid COOH THR1242 OH ASN1245 NH2 2.23 1.99 Hydroxyphenyl OH Dihydroxychromane OH ASN437 C = O ARG1300 NH2 2.31 2.37 2.23 2.17 Caffeoyl OH Caffeoyl OH Caffeoyl C = O Hexose CH2OH ARG388 NH2+ ARG388 NH2+ ARG1246 NH2+ ASN1293 NH2 2.27 2.03 Dihydroxychromone C = O Dihydroxychromone OH ARG1246 NH2+ ARG1246 NH2+ 2.30 2.14 Dihydroxychromanone C = O Dihydroxychromanone OH ARG1246 NH2+ ARG1246 NH2+ Binding modes to SUR1 (continued): Compounds (A) 11 (caffeoylferuloylquinic acid), (B) 12 (isorhamnetin), (C) 13 (malaferin B), (D) 14 (chicoric acid hexoside isomer), (E) 15 (taxifolin), (F) 19 (methoxyapigenin), (G) 21 (eriodyctiol), and (H) 25 (pinocembrin). Ligands are displayed as balls and sticks, while residues are shown as tubes. Hydrogen bonds are depicted as yellow dashed lines with their lengths in magenta. Discussion Medicinal plants are often used to prevent and treat human diseases due to their phenolic compounds65. Many studies have shown that plants with antihyperglycemic effects act through multiple mechanisms, including improving insulin sensitivity in target cells, increasing insulin secretion, and promoting β-cell regeneration in the pancreatic islets of Langerhans66. Several researchers have identified flavonoids and phenols as major contributors to their antidiabetic effects67. In this context, this study evaluated the antidiabetic, anti-inflammatory, and antioxidant potential of A. monosperma DAME. The anti-inflammatory activity of DAME from A. monosperma was proven by a reduction in TNF-α and CRP expression in response to LPS stimulation of RAW macrophages. This effect may be linked to the presence of hydroxycinnamic acids68. The anti-inflammatory activity of DAME may reduce inflammation-driven insulin resistance and enhance blood glucose regulation by modulating macromolecular signaling. Furthermore, the anti-inflammatory properties of DAME, along with its demonstrated ability to promote wound healing, may improve delayed wound-healing problems in diabetes69. The DAME is rich in phenolic compounds, such as hydroxycinnamic acids and flavonoids, which possess significant anti-inflammatory activity70,71. Enhancing antioxidant capacity is a key therapeutic approach for managing diabetic complications related to oxidative stress. Due to their phenolic compounds, which are associated with enhanced antioxidant capacity, the interest in medicinal plants has grown72. DAME’s antioxidant capacity underscores its potential to exert antioxidant and antidiabetic effects by reducing oxidative stress and/or enhancing the antioxidant system. Based on phenolic content, the extract exhibits potential reducing power and scavenging activity, which correlate with its promising antioxidant capacity, as demonstrated herein by DAME’s ability to scavenge DPPH, superoxide, and NO radicals72. Phenolic compounds, such as hydroxycinnamic acids and flavonoids, can reduce free radicals, including superoxide anions, which are ordinary free radicals increased during oxidative stress, originating from auto-oxidation or enzymatic reactions leading to additional oxidative damage73; by boosting antioxidant enzyme activity, thereby increasing antioxidant values, as seen in this study68. A. monosperma DAME might strengthen the antioxidant system in diabetes by directly neutralizing free radicals and may also help lower hyperglycemia by improving insulin sensitivity and reducing β-cell damage. Nitric Oxide (NO) is a key biological mediator and a free radical generated under physiological conditions by almost all mammalian cells. It concerns the regulation of the cardiovascular and immune systems in mammals. Excess NO levels are associated with several diseases42. The nitric oxide synthase (NOS) enzyme family produces NO by converting L-arginine into L-citrulline and NO via oxidation reactions. These enzymes consist mainly of two domains: An N-terminal oxygenase domain and a C-terminal reductase domain, both connected by a calcium-calmodulin binding region74,75. There are three main isoforms of NOS: neuronal, inducible, and endothelial, among which iNOS is induced by inflammatory cytokines or pathogens to produce large amounts of NO to combat inflammation or infection74–77. NO acts as a defense molecule against infectious microorganisms and regulates the development, activity, and death of various inflammatory and immune cells78. However, overexpression or dysregulation of iNOS results in excessively high NO levels, which are linked to multiple diseases such as inflammatory conditions, rheumatoid arthritis, and diabetes. Therefore, controlling the expression and activity of iNOS is essential for maintaining its beneficial functions and preventing its harmful effects43,76,77. Thus, all compounds 1–25 were virtually screened against the iNOS active site within the oxygenase domain, which contains the substrate-binding site and the heme cofactor, to help identify potential inhibitors. The compounds fit into the active site, including the main residues GLN263, ARG266, TYR347, PRO350, and ARG388, as well as heme. While docking the co-crystallized ligand (AT2) achieved an energy of −8.9 kcal/mol (Table 6; Fig. 4A), ten compounds had much better binding affinities to iNOS. According to their chemical classification, the top compounds are cinnamic acids 9, 11, 17, 14, 22, and 1; lignan 4; catechin 13; flavanone 21; and flavonol 15. Within the energy range from − 8.9 to −7.0 kcal/mol, there were fourteen ligands, including cinnamic acids 5, 6, and 24, catechin 18, flavonone 25, flavonol 12, flavones 16 and 19, phenolic acids 8 and 20, sesquiterpenes 7, 10, and 23, alongside resorcinol 3. The phenolic acid 2 ranked last in binding to iNOS, with a binding energy of −6.3 kcal/mol (Table 6). Consequently, among compounds 1–25, the identified cinnamic acids and lignans appear to be the most promising as iNOS inhibitors, followed by the catechins, flavanols, flavonones, and flavones. The identified resorcinol, sesquiterpenes, and phenolic acids could be the least promising. The interactions of the top ten ligands with iNOS are detailed in Table 7; Figs. 4B–H, and 5A–C. These primarily involved hydrogen bonding and π-π stacking. Compound 1 formed a hydrogen bond between its caffeoyl C = O and GLN263 (Fig. 4B), while Compound 4 formed a hydrogen bond between its benzodioxole oxygen and VAL352 (Fig. 4C). Compound 9 showed four hydrogen bonds: one between the propenoate oxygen and GLN263, another between quinic acid COOH and TYR347, and two involving caffeoyl OH groups with TRP372 and GLU377 (Fig. 4D). Compounds 1, 4, and 9 also participated in π-stacking with the heme via the caffeoyl ring in compounds 1 and 9, and through the benzodioxole ring in compound 4. The caffeoyl C = O and quinic acid COOH of compound 11 formed hydrogen bonds with TYR347 and ASP382, respectively. Also, its aromatic rings were π-stacked with heme (Fig. 4E). Compound 13 formed hydrogen bonds with GLN263 and TYR373 via its propenoate oxygen and dihydroxychromane OH, respectively, and its hydroxyphenyl group π-stacked with heme (Fig. 4F). Compound 14 had its caffeoyl C = O and OH groups hydrogen-bonded to TYR347 and PRO350, respectively (Fig. 4G). Compound 15 engaged in π-stacking with heme through its catechol moiety (Fig. 4H). Compound 17 interacted through its caffeoyl C = O and propanoic COOH with TYR347, TYR373, and ASP382, and via its catechol OH with heme (Fig. 5A). The dihydroxychromanone C = O and catechol OH of compound 21 were bound to TYR347 and VAL352 (Fig. 5B). Compound 22 exhibited hydrogen bonds with GLN263 and ASP382 via its propenoate oxygen and quinic acid OH, respectively, and π-stacked with heme through its caffeoyl ring (Fig. 5C). According to previous reports, caffeoylquinic acid isomer (1)79 was reported for its potential as an iNOS inhibitor through in-vitro and in-silico study showing binding affinity that coincides with our reported results. Ejembi et al. (2021)80 reported the binding affinity of several phenolic derivatives identified from A. annua, including caffeoylquinic acid and di-O-caffeoylquinic acid, as iNOS inhibitors, and their results also showed a binding affinity score that matched ours80. In pancreatic β-cells, the ATP-sensitive potassium (KATP) channel regulates insulin secretion based on blood glucose levels. The channel consists of four pore-forming subunits constituting the inward rectifying potassium channel (Kir6.2), surrounded by four regulatory sulfonylurea receptor 1 (SUR1) subunits1,81. SUR1 is part of the ATP-binding cassette (ABC) transporter superfamily, which transports different molecules across cell membranes44,82. Each SUR1 contains two transmembrane domains (TMD1 and TMD2), two cytoplasmic nucleotide-binding domains (NBD1 and NBD2), and an N-terminal transmembrane domain (TMD)81,83. Sulfonylureas and glinides are two types of insulin secretagogues used to treat type 2 diabetes. They bind to a specific pocket between the transmembrane (TM) α-helices of TMD1 and TMD2 in SUR1, reducing insulin secretion and lowering high blood glucose levels44,82. Compounds 1–25 were also in silico screened against the binding site of sulfonylureas and glinides to assess their potential as SUR1 inhibitors. A receptor structure in complex with glibenclamide, a sulfonylurea analog of gliclazide used in the antidiabetic screening, was selected. Docking the co-crystallized glibenclamide yielded a binding energy of −10.4 kcal/mol (Table 6; Fig. 5D). The identified lignan 4 showed stronger binding to SUR1, with an energy of −11.0 kcal/mol. Additionally, the cinnamic acid 9 obtained a comparable binding energy of −10.3 kcal/mol to that of glibenclamide. Moreover, eight other ligands achieved energy scores of ≤ −9.0 kcal/mol. Based on their classification, these top ten compounds include lignan 4, cinnamic acids 9, 11, and 14, flavonols 12 and 15, flavanones 21 and 25, flavone 19, and catechin 13. Among the remaining ligands, thirteen attained energy scores between − 8.9 and − 7.0 kcal/mol, involving cinnamic acids 1, 5, 17, 22, and 24, sesquiterpenes 7, 10, and 23, flavone 16, catechin 18, phenolic acids 8 and 20, and resorcinol 3. Cinnamic acid 6 and phenolic acid 2 exhibited the weakest binding to SUR1, with binding energies of −6.8 and − 6.1 kcal/mol, respectively (Table 6). Thus, the identified lignans, flavonols, and flavonones are the most promising SUR1 inhibitors, followed by cinnamic acids, flavones, and catechins. The identified sesquiterpenes, phenolic acids, and resorcinol could be the least promising. Presented in Table 8; Figs. 5D–F, and 6A–H are the binding interactions of the top ten binding ligands to SUR1. The compounds accommodated the same binding site as sulfonylureas and glinides, located between the TMs of TMD1 and TMD2, particularly TM7 and TM8 of TMD1, and TM16 and TM17 of TMD2. Compound 4 possessed hydrogen bonds between two of its benzodioxole oxygens and ASN437 and ASN1245, and between one of its hexahydrofurofuran oxygens and ARG1246 (Fig. 5E). Compound 9 formed hydrogen bonds between two caffeoyl OH groups and SER376 and ARG388, and between a caffeoyl C = O and both ASN1245 and ARG1246 (Fig. 5F). Compound 11 hydrogen-bonded to both THR1242 and ASN1245 through its quinic acid COOH moiety (Fig. 6A). A single hydrogen bond was disclosed between the trihydroxychromone C = O of compound 12 and ARG1246 (Fig. 6B). Compound 13 formed two hydrogen bonds: one between the hydroxyphenyl OH and ASN437, and another between the dihydroxychromane OH and ARG1300 (Fig. 6C). Compound 14 exhibited hydrogen bonds between two caffeoyl OH groups and ARG388, the caffeoyl C = O and ARG1246, and the hexose CH2OH and ASN1293 (Fig. 6D). ARG1246 showed significant hydrogen bonding to the trihydroxychromanone C = O of compound 15 (Fig. 6E), both the dihydroxychromone C = O and OH of compound 19 (Fig. 6F), the dihydroxychromanone C = O of compound 21 (Fig. 6G), and both the dihydroxychromanone C = O and OH of compound 25 (Fig. 6H). Conclusions The HPLC/HRMS of A. monosperma DAME revealed the presence of 25 metabolites, mainly phenolic derivatives. DAME produces antihyperglycemic activity and significantly improves glucose tolerance compared to the control. Additionally, it exhibits notable anti-inflammatory and antioxidant activities, and the wound-healing rate with DAME was significantly higher than that in the control group (p < 0.001). Molecular docking of compounds 1–25 showed their fitting into the heme-containing active site of iNOS and the sulfonylurea binding site of SUR1. Several compounds exhibited higher binding affinities than the co-crystallized ligand for each target, indicating they may act as potential inhibitors of iNOS or SUR1. Notably, lignan four and cinnamic acids 9, 11, and 14 achieved remarkable binding affinities for both iNOS and SUR1. A. monosperma is considered a potential bioactive agent for the treatment of diabetes and inflammation. Nonetheless, additional research is needed to confirm their safety in clinical settings. Furthermore, additional OECD-compliant acute and subchronic toxicity studies are necessary to fully characterize the safety profile of A. monosperma DAME. Abbreviations Type 1 diabetes mellitus Type 2 diabetes mellitus Defatted aqueous methanol extract of the aerial parts High-resolution high-performance liquid chromatography coupled with mass spectrometry Quadrupole time-of-flight liquid chromatography/mass spectrometry Sucrose-loaded model Blood glucose level High-fat diet Dulbecco’s modified eagle medium 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide C-reactive protein Tumor necrosis factor-alpha Quantitative reverse transcription polymerase chain reaction Human foreskin fibroblast cells 2,2-diphenyl-1-picrylhydrazyl Superoxide radical Dimethyl sulfoxide Half-maximal inhibitory concentration Nitric oxide Total antioxidant capacity Inducible nitric oxide synthase Sulfonylurea receptor 1 Protein Data Bank Root mean square deviation Lipopolysaccharides Reactive oxygen species ATP-sensitive potassium Cytoplasmic nucleotide-binding domain N-terminal transmembrane domain Transmembrane Author contributions HB: methodology, validation, revising the first draft, and finalizing the manuscript MSM: methodology, validation, revising the first draft, and finalizing the manuscript, ON: docking methodology, validation FM: Investigation, conceptualization, revising the first draft, and finalizing the manuscript. NT: methodology, validation, revising the first draft, and finalizing the manuscript, NH: Investigation, methodology, validation, resources, revising the first draft, and finalizing the manuscript. All authors approved the manuscript submission. Funding Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). Data availability All data generated or analyzed during this study are included in this published article [and its supplementary information files]. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Hanaa B. Atya, Mohamed S. Mady, Nashwa F. Tawfik and Nashwa E. Hashad contributed equally to this work. References Associated Data Data Availability Statement All data generated or analyzed during this study are included in this published article [and its supplementary information files].